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ABSTRACT
IMMOBILIZATION OF RHODOCOCCUS ERYTHROPOLIS AS A POTENTIAL
TREATMENT FOR ATHEROSCLEROSIS
by Srikanth Vivek Darbha
Cardiovascular disease is the leading cause of death in the United States and is
primarily due to hypercholesterolemia. The novel approach of combatting
atherosclerosis presented in this research entails delivery of microencapsulated
Rhodococcus erythropolis immobilized in biodegradable alginate-based microcapsules
and utilizing the bacterium’s cholesterol oxidase enzyme pathway to degrade cholesterol
from intermediate-stage arterial plaque. The bacterial growth medium was optimized
using Taguchi design methods to enable growth characterizations hindered by
biosurfactant by-product. Methodologies for extraction and quantification of
biosurfactant and cholesterol were developed and conducted simultaneous to bacterial
growth assessment. Bacteria were encapsulated using atomization (850±50 µm) and
inkjet bioprinting (32±5 µm) to study the effects of cell density and capsule
miniaturization on the rate of cholesterol degradation. The cholesterol degradation rate
was determined to be independent of cell density, and capsule miniaturization led to a
near 4-fold increase in cholesterol degradation, thus allowing for 61.8% cholesterol in an
intermediate-stage lesion to be degraded.
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1.0 INTRODUCTION!
1.1 Background
Atherosclerosis is considered to be an inflammatory condition of the artery and is
characterized by the narrowing due to buildup of a substance known as plaque. It is one
of the leading causes of death for men and women in the United States (Moses, 2007;
Fontos, 2006; Sutton, 2005; Arjomand, 2003; Jenkins, 2002; Bitl, 1995; Serruys, 1994),
and a wide variety of common ailments are associated directly with it, including
cardiovascular disease (CVD), coronary heart disease (CHD), hyperlipidemia, and
hypercholesterolemia.
Hyperlipidemia is the leading cause of cardiac illness and death (Rosamund,
1998; Murray, 1997), specifically CHD, ischemic cerebrovascular disease, and peripheral
vascular disease (Jain, 2007). It had been established in 1984 that cholesterol was
directly linked to CHD (McGill, 1968) such that a 1% drop in blood cholesterol levels led
to a 2-3% reduced risk for CHD (AHA, 2001). This is a significant statistic because
CHD accounts for twice as many cancer-related deaths and ten times as many accidentrelated deaths (McGill, 1968). According to the World Health Organization (WHO),
high cholesterol levels accounted for over 60% of CHD cases (Yusuf, 2004). Cholesterol
is also known to lead to damage in endothelial (arterial) tissue (McGill, 1968). This was
apparent in Europe where 45% of heart attacks in Western Europe and 35% in Central
and Eastern Europe were due to high cholesterol (Yusuf, 2004).
Along with CHD and hypercholesterolemia, CVD assumes a large portion of the
cardiovascular market. Some major risk factors for CVD include health conditions of
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large markets, including diabetes and hypertension, for example (George, 2010). In
2002, over 62 million patients suffered from CVD in the U.S. alone, and the total costs of
treatment amounted to over $110 billion (du Souich, 2004). It has been projected that by
year 2030, CVD will remain the leading cause of death in the world (WHO, 2009). In
Europe especially, CVD takes its toll with over 4 million deaths per year, 38% of which
occur in the UK (WHO, 2009).
One must also consider the corresponding market of cardiovascular stents, in
particular the drug-eluting stents (DES). In 2005, it was estimated that DESs constituted
a market of approximately $5 billion (Congress, 2010). In 2006, DESs accounted for
over 70% of the stent market in the U.S. and 40% in Europe (Ong, 2006). In 2009,
approximately 80% of stents in the U.S. were of the DES subset (Maisel, 2007), and
healthcare spending amounted to over $400 billion in the U.S. (Mensah, 2007). It is
projected that the market for DESs will amount to over $6 billion annually in the U.S.
(Bischof, 2009).
1.2 Physiology of Atherosclerotic Plaque
Plaque is composed of cholesterol-filled macrophages, smooth muscle cells
(SMC), glycosaminoglycans (GAG), collagen, fibrin, and cholesterol (Ross, 1976). What
causes atherosclerosis to progress is the formation of an atherosclerotic lesion, which
occurs when low-density lipoprotein (LDL) breaches the damaged intima of the blood
vessel (Brown, 1983). The LDL is then oxidized, which causes the release of adhesion
factors and chemotactic molecules (Moubayed, 2007). These adhesions molecules in
turn allow for freely flowing blood monocytes to adhere and bind to the endothelial layer
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of the vessel wall (Moubayed, 2007). Specifically, the monocytes appear at the intima
and subintima of the vessel wall (Imhof, 2004; Ley, 2007).
Blood monocytes are an unbound species naturally present in blood and circulate
to regions of inflammation in order to produce cytokines (Woollard, 2010). They are also
capable of differentiating into macrophages and even foam cells (Tacke, 2006; Varol,
2009) they can consume oxidized LDL (Woollard, 2010) by way of receptor-mediated
endocytosis (Goldstein, 1979; Basu, 1979; Goldstein, 1980; Goldstein, 1981). Next, is
that the monocytes/macrophages consume oxidized LDL (Greaves, 2009) and then
differentiate into foam cells, so named due to their foamy appearance similar to soapy
lather. It is the cholesterol that is stored as cholesteryl ester droplets within the
macrophages/monocytes that contributes to the foamy appearance (Greaves, 2009). Also,
the cholesterol that is endocytosed undergoes a continuous cycle of hydrolysis and reesterification by various lysosomal enzymes (Brown, 1980). The accumulation of these
foam cells, also known as fatty streaks, is the early stage of plaque that is incorporated in
the intima layer of the vessel (Galkina, 2009). It is important to note that fatty streaks
usually develop in those regions that have arterial branching (Hahn, 2009).
The fatty streaks then accumulate and mature into a plaque core that is eventually
surrounded by a cap of smooth muscle cells and a collagen cellular matrix (Woollard,
2010). During this time, a plethora of inflammatory cytokines and growth factors is
secreted and furthers the progression of the plaque, which can eventually lead to
thrombosis and even stenosis (Woollard, 2010). Consequently, the plaque core becomes
necrotic and can cause new blood vessels to form (Woollard, 2010). The cap surrounding
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the plaque is capable of breaking off in the form of debris, thereby leading to cascades of
coagulation and clotting (Fuster, 2005).
Atherosclerosis is categorized into six stages (HVIF, 2010), outlined below:
•

Stage I, is a normal healthy artery with no damage or blockages.

•

Stage II is characterized by the presence of fatty streaks that appear vertically thick in
the vessel wall. However, there are no apparent symptoms of atherosclerosis o or any
obstructions.

•

As the fatty streaks accumulate, the vessel enters Stage III and an atheroma begins to
develop, thereby interfering with normal blood flow.

•

Stage IV is characterized by plaque maturation and hardening in which case over
50% of the vessel diameter is available for blood flow. This results in high blood
pressure and heart rate for the suffering individual.

•

During Stage V, the plaque may be subject to cracking in which clots may adhere.
This can contribute to a progressed blockage, thereby leading to a significantly
reduced blood flow to the heart such that prolonged angina may develop.

•

Stage VI is the most advanced stage at which clots may potentially obstruct the entire
vessel lumen diameter.

1.3 Current Treatment Methods for Atherosclerosis
1.3.1. Pharmaceutical!
The main conventional treatment for atherosclerosis includes synthetic substances
that fall into a class of drugs known as statins, which function to lower cholesterol levels
through the inhibition of an enzyme (HMG-CoA reductase) that is responsible for
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cholesterol production in the liver. Although effective for atherosclerotic treatment,
statins have been shown to lead to death or non-fatal myocardial infarction (Athyros,
2009). Patients who discontinue the use of statins are set up for more adverse coronary
complications (Athyros, 2009), especially during any subsequent surgery (Schouten,
2007). Since patients must not consume oral medication after surgery and there are no
intravenous forms of statins, the discontinuation of statins during the surgery may lead to
postoperative troponin release, myocardial infarction, or cardiovascular death (Athyros,
2009).
Another method of treatment that has gained attention is EDTA chelation therapy,
which is claimed to be effective for atherosclerotic plaque degradation (Ernst, 2000;
Ernst, 1997; Lewin, 1997). EDTA chelation therapy comprises a strong market to the
extent that out-of-pocket costs range from $400 million to $3 billion annually in the U.S.
(Knudston, 2002; Lamas, 2000).
1.3.2 Cardiovascular Stents
Apart from pharmaceutical treatment, cardiovascular stents are being used in
order to widen arterial lumen and thus allow blood flow to be unhindered. Stents are
typically placed into the coronary artery by way of a catheter and guide wire and then
deployed during angioplasty. The various types of stents that exist today are the result of
an evolutionary transformation from traditional bare metal stents, to polymer stents, to
the highly studied bioabsorbable stents that are gaining attention for their reduced risk of
restenosis (Camenzind, 2007; Pfisterer, 2006; Tsimikas, 2006), which is the re-narrowing
of an artery after it has been unblocked.
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According to Rajagopal, et al, two possible mechanisms have been hypothesized
for the invocation of the restenosis phenomenon: arterial modeling and neointimal
hyperplasia (Rajagopal, 2003). There are two proposed types of arterial modeling that
exist: positive and negative. Positive remodeling involves enlargement of the coronary
artery in response to plaque formation in order to limit luminal occlusion (Glagov, 1987).
Negative remodeling involves further luminal occlusion in response to plaque buildup,
thus contributing to restenosis (Rajagopal, 2003). Neointimal hyperplasia involves a
cellular cascade that ultimately results in proliferation of smooth muscle cells upon
plaque rupture by way of balloon inflation from angioplasty (Pakala, 1997; Dorn II,
1997).
It has been shown that bare metal stents have led to significantly increased risk for
restenosis (Tsimikas, 2006; Pakala, 1997; Dorn II, 1997), thereby requiring the use of
dual antiplatelet therapy for prevention of restenosis. Such therapy can lead to long-term
bleeding, and the efficacy of it is still unproven (Doyle, 2009). Hence, polymer stents
were developed, but have been shown to lead to late thrombosis and are associated with
diminished arterial healing, which is associated with delayed re-endothelialization and
the continued presence of fibrin (Pfisterer, 2006; Joner, 2006; John, 2008). Drug-eluting
polymer stents were then developed to combat restenosis, but have been shown to be
associated with inflammatory cell infiltration and possibly even arterial drug
sequestration (Virmani, 2004; Carter, 2004; Finn, 2005), which may lead to arterial
toxicity (Hoye, 2006; Kuchulakanti, 2006; Takano, 2006). Hence, increases in drug
concentration may be counterproductive for restenosis treatment. It has been shown that
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luminal caliber significantly decreases after 6-8 months of drug-eluting polymer stent
implantation and is due to the continued inflammatory response in the arterial wall
(Byrne, 2009), which may be a result of residual polymer in the artery (Joner, 2006;
Virmani, 2004; Finn, 2007).
In order to avoid issues with metallic and polymer stents, bioabsorbable stents are
being studied. One such popular stent on the market is the EXCEL Sirolimus eluting
stent, which is made of poly-lactic acid and degrades into CO2 and H2O by-products
(Doyle, 2009). EXCEL is associated with 5.4% restenosis and elicits no myocardial
infarction, thrombosis, or death, thereby proving its initial safety and efficacy (Doyle,
2009).
Since pharmaceutical treatments for atherosclerosis are very expensive and can
lead to complications that may be fatal in nature, there is an imperative need to research
and develop alternative treatment methods that are safe, effective, and inexpensive. One
such alternative that is gaining much attention is the concept of cell encapsulation, which
is the central aim of this research effort. Advantages of encapsulation include the
presence of a biocompatible immunoisolation barrier for cell encapsulation, ensuring that
the cells do not come into contact with blood (DeVos, 1997).
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2.0 LITERATURE REVIEW!
2.1 Cholesterol-Degrading Bacteria
Various strains of bacteria can degrade cholesterol through enzymatic pathways
(ATCC, 2010). Shown in Table 1 is a tabulated list of such bacteria as identified by the
American Type Culture Collection (ATCC).
Table 1. Bacteria information and availability (ATCC, 2010).
ATCC No.
43121
4277
14811
17825
25544
31216
*31384
*31385
*31455
*31456
*31457
*31458
*31459
*31460
**35215
51222
BAA-148

Biosafety
Level
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

ATCC Medium
#
416
196
196
3
3
44
1374
1374
1374
1374
1374
1374
1374
1374
1317
1872
1872

Temperature of Growth (°C)
34
26
26
26
26
26
30
30
30
30
30
30
30
30
30
37
37

The ATCC numbers with one asterisk correspond to those bacteria that grow on
cholesterol media; the number with two asterisks corresponds to the bacterium that
degrades cholesterol. The bacterium of interest (in bold) in this study was ATCC 25544,
also known as Rhodococcus erythropolis. This species has the ability to produce
biosurfactant compounds that are directly dependent upon the growth medium. A
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glycolipid compound known as trehalose lipid (shown in Fig. 1) is produced by R.
erythropolis when grown on a hydrocarbon medium (Franzetti, 2010).
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Figure 1. Chemical structure of Rhodococcus sp. trehalose lipid.!
Glycolipids are sugar molecules (mono or disaccharides) attached to fatty acids.
The sugar moiety is polar, whereas the lipid moiety is non-polar, thus rendering it
amphipathic. Glycolipids produced by R. erythropolis decrease the surface tension and
interfacial tensions of culture broth to 25-40 mN/m and 1-5 mN/m, respectively (Li,
1984; Rapp, 1979; Kretschmer, 1982). Several hypotheses have been formulated to
explain this phenomenon: (i) the biosurfactant may aid in survival, (ii) the biosurfactant
may aid in transport of nutrient, (iii) the biosurfactant may lead to reduced
hydrophobicity of the culture broth (Franzetti, 2010).
This particular strain produces the enzyme cholesterol oxidase that specifically
degrades cholesterol (Eqn. 1) and has a molecular mass of approximately 55 kDa (Sojo,
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1997). Cholesterol oxidase, 3!-Hydroxysteroid:oxygen oxidoreductase, is an enzyme
that catalyzes the oxidation of cholesterol into cholest-4-en-3-one (Kreit, 2009).
!!!"#$%#&!" ! !!

!!!"#$%#&!"!!"#$%&'

!! !! ! ! ! !!!"#$%#! ! ! ! !"#

(1)

Although H2O2 is a known cytotoxic chemical, it is naturally decomposed by
peroxisomes of the human body and can be cleared by the enzyme catalase (Eqn. 2).
!!! !!
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!!! ! ! !!

(2)

Cholesterol oxidase is derived from several microbial sources, including
Arthrobacter (Wilmanska, 1988), Corynebacterium (Shirokane, 1977), R. erythropolis
(Richmond, 1973; Atrat, 1992), Nocardia rhodochrous and Rhodococcus rhodochrous
(Buckland, 1976; Aihara, 1986; Cheetham, 1980; Cheetham, 1982; Cheetham, 1979;
Minuth, 1995), Mycobacterium (Schatz, 1949; Smith, 1995), Pseudomonas (Rhee, 1991),
Schizopyllum commune (Fukuyama, 1979), Brevibacterium sterolicum (Uwajima, 1973;
Ohta, 1991), Streptoverticillium cholesterolicum (Inouye, 1982), Streptomyces violascens
(Ishizaki, 1989; Lartillot, 1990; Kamei, 1978), and Rhodococcus sp. (Watanabe, 1986;
Kreit, 1992; Watanabe, 1989). The enzyme’s activity is optimal at a pH of 7.0 and 37°C.
Other physical properties vary from species to species. Sojo, et al report that the ATCC
25544 strain produces both intracellular (cell-bound) and extracellular cholesterol
oxidase, but more intracellular cholesterol oxidase is produced than extracellular
cholesterol oxidase (Sojo, 1997).
Applications of cholesterol oxidase have been mainly geared towards cholesterol
quantification through use as an analytical probe. The utility of the enzyme is vast in
application and has been studied with regards to cholesterol quantification of the
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following: total and esterified serum (Kreit, 2009; Shirokane, 1977; Allain, 1974; Brooks,
1983; Murata, 1992; Lapinleimu, 1994; Gray, 1995); LDL (Sugiuchi, 1998) and HDL
(Cobbaert, 1998); cholesterol on the erythrocyte cell membranes (Lange, 1984); gall
stones (Wei, 1989); human bile (Aufenanger, 1989; Bocos, 1992); fluorescence (Gray,
1995) and chemiluminescence (Mike, 1992; Sasamoto, 1995) detection methods.
Cholesterol oxidase has also been integrated into a rapid bioreactor to measure serum
triglyceride and total cholesterol (Makino, 1987).
Due to the diversity of the enzyme’s applications, many efforts have been
expended on optimizing cholesterol oxidase production, which has been deemed as an
expensive process due to low productivity. Hence, efforts of cloning and genetic
manipulation are of high interest to optimize production.
2.1.1 Bacteria Growth Curve Theory!
Shown in Fig. 2 is a standard bacteria growth curve. There are four main phases,
namely lag, log, stationary, and death/decline phases. The lag phase occurs immediately
after the bacteria culture is created. During this phase, the bacteria cells are adapting to
the new environment. It is important to note that the cells are still active. It is during this
phase that the intracellular enzyme is produced (Shuler, 2002). The log phase is the time
during which the cells begin to actively replicate and grow at an exponential rate.
Because nutrition is limited, there are a finite number of cells that can grow. That is, the
cells reach saturation at which point cell growth begins to cease. The point at which the
cell growth rate is equal to the cell death rate is when the population begins to stabilize
and enters what is known as the stationary phase. It is during this stationary phase that
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extracellular enzyme is produced (Shuler, 2002). The final phase for the cells is the
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death/decline phase, which is when the cell death rate exceeds the cell growth rate.
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Figure 2. Bacterial growth curve.

2.2 Biocompatibility of Alginate
Alginate is a polymer that is composed of "-L-guluronic acid (G) and !-Dmannuronic acid (M) blocks (Nunamaker, 2007). Depending on the ratio of these blocks,
properties of the alginate material can be altered accordingly. A higher percentage of G
results in alginate that is stronger, while a higher percentage of M results in a more
flexible gel (Amsden, 1999). The range of flexibility changes according to the following
order: MG > MM > GG (Smidsrod, 1973). Part of the reason why higher G alginates are
stronger is due to the greater number of cross-links that form as a result of the higher
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affinity of Ca2+ for the G sites (Kong, 2004). High G alginates are known to exhibit high
permeability to antibodies (Klein, 1983; Stewart, 1993), which may potentially weaken
its biocompatibility. This increased biological response may be quelled through the use
of alginate that consists of 40-45% G and is high purity (Fritschy, 1994; De Vos, 1997;
De Vos, 1993; De Vos, 1994; De Vos, 1997).
2.3 Microcapsule Technology
2.3.1 Atomization
Alginate microcapsules are used extensively because of the controllable range of
membrane permeability and the ease of solvent free microcapsule synthesis steps
conducted at the physiological pH of 7.4. To immobilize enzyme bio-compound within
alginate microcapsules, the compound at a specific concentration is suspended in medium
viscosity sodium alginate and atomized into 10 % (w/v) CaCl2 cross-linking solution
(Stewart, 1993). The atomizer design (Fig. 3) is comprised of two concentric channels
such that coaxial airflow shears the liquid droplets in a reproducible manner. Droplet
size can be controlled by adjusting the coaxial airflow rate (FA), the compound/Naalginate suspension flow rate (FL), and the radial dimensions of the atomizer.
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Figure 3. Design of atomization needle (drawing not to scale).!
2.3.2 Inkjet Bioprinting
Inkjet printing involves ejecting liquid droplets from a printhead (Fig. 4) by way
of various modes of impulses, including acoustic, thermal, or piezoelectric (Martin, 2008;
Le, 1998; Brunahl, 2002), which cause the pressure plate to oscillate back and forth,
thereby releasing ink droplets. The main advantages of inkjet printing include the


miniaturization capability for droplet generation on the order of 10 µm (Dong, 2006) and
method reproducibility. The major disadvantages, however, are that this is a highly
meticulous and time-consuming process, with regards to jetting biological fluids nonNewtonian and highly viscous in nature (Dohnal, 2010).
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Figure 4. Cross-sectional view of inkjet printhead (drawing not to scale).!
2.4 Extraction Theory
Extraction theory is based off of how a solute is distributed within a 2-phase
system at equilibrium (Fournier, 2007). Suppose that N1 moles of solute are (initially)
mixed in N2 moles of aqueous liquid (phase II) and N3 moles of organic solvent (phase I),
which has high selectivity for the solute. Described in Eqn. 3 is the distribution of these
three components amongst the two immiscible phases at equilibrium.
!!! !!! !!! !!! !! ! !!!! !!!! !!!! !!! !!

(3)

where !!! and !!!! are the activity coefficients of component i in phases I and II,
respectively, !!! and !!!! are the mole fractions of component i in phases I and II,
respectively, and !!! !!! !! and !!!! !! ! are the pure component fugacities of component
i in phases I and II, respectively, as a function of temperature and pressure. Since
component i does not change state in either phase at the same temperature and pressure,
the pure component fugacities of component i are the same in either phase. Hence, Eqn.
3 becomes:
!!! !!! ! !!!! !!!!
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(4)

where !!! and !!!! are the activity coefficients of component i in phases I and II,
respectively, and !!! and !!!! are the mole fractions of component i in phases I and II,
respectively. Eqn. 4 can then be rearranged in order to obtain the partition coefficient K
(Eqn. 5), which is the ratio of mole fractions of component i in either phase.
!!

!!!
!!!
!
!!!! !!!!

(5)

where K is the partition coefficient, !!! and !!!! are the activity coefficients of component i
in phases I and II, respectively, and !!! and !!!! are the mole fractions of component i in
phases I and II, respectively.
Shown in Fig.5 is the extraction scheme used in this research study.
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Figure 5. Cholesterol extraction scheme!
The partition coefficient, K, can be calculated as given in Eqn. 6.
!
!!"#
! ! !!
!!"#

(6)

!
where ! is the partition coefficient, !!"#
is the final mole fraction of solute in the
!!
organic phase, and !!"#
is the final mole fraction of solute remaining in the aqueous

phase.
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2.5 Prior Studies with Cholesterol-Degrading Bacteria
Many strains of cholesterol-degrading bacteria strains have been identified and
studied in the literature. For this study, a literature survey was conducted on bacteria
capable of producing cholesterol oxidase enzyme. Shown in Table 2 is a summary of the
literature survey of prior cholesterol degradation experiments. Data of interest included
those that pertained to microbial degradation of cholesterol as opposed to extraction of
microbial-derived enzyme followed by cholesterol degradation.
Johnson, et al (Johnson, 1990) studied cholesterol degradation by R. equi in BHI
growth medium containing an initial cholesterol concentration of 125 µg/mL. They
reported that up to 80% of cholesterol was degraded over a 7-day period by 10 of 27
cultures. The same authors also studied cholesterol degradation in egg yolk and milk
cream by R. equi. 33706. It was reported that 40% of egg yolk cholesterol was degraded
in 60 min, and 2.36% of milk cream cholesterol was removed in 60 min.
Bianchi, et al (Bianchi, 1996) used bacteria strains ATCC 25544, ATCC 4277,
and ATCC DSM20131 to compare cholesterol degradation rates for the cases of free and
encapsulated bacteria in chitin. Cell concentrations were taken from the exponential
growth phase. It was seen that after 3 days, free bacteria had degraded nearly all
cholesterol, and the encapsulated bacteria degraded 97% of all cholesterol. Tok, et al
(Tok, 2010) used various strains of Lactobacillus delbrueckii subsp. bulgaricus (ATCC
11842) for cholesterol degradation for the cases of free and encapsulated bacteria in Caalginate.
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Table 2. Summary of literature survey to-date of prior cholesterol degradation studies using bacteria.

Study
Johnson,
et al
Johnson,
et al
Johnson,
et al
Bianchi,
et al
Tok,
et al
Goetschel,
et al

Garofalo,
et al

Gilliland,
et al

!

Organism
R. equi
R. equi 33706
R. equi 33706
ATCC 25544,
4277, DSM20131
ATCC 11842
ATCC 25544

P. pictorum

L. acidophilus

Solvent/Medium
n-propanol,
BHI
n-propanol,
BHI
n-propanol,
BHI
DMF,
Agar slant
Ethanol,
MRS Broth
Aqueous (2,2’dipyridal +
phosphate buffer)

Serum

Serum, MRS Broth,
oxgall

Substrate

Membrane

Degradation Results

Cholesterol

Free

80% in 7 days

Egg yolk

Free

40% in 60 min

Milk cream

Free

2.36% in 60 min

Free,
Chitin
Free,
Ca-alginate

Nearly all in 3 days,
97% in 3 days
31%,
31% in 48 h

Johnson,
1990
Johnson,
1990
Johnson,
1990
Bianchi,
1996
Tok,
2010

Cholesterol

Free,
Liposomes

33% in 24 h,
98% in 16 h

Goetschel,
1992

Cholesterol

Free,
Open pore
agar,
Alginate,
Poly-llysine

25% in 12 days,
50% in 12 days

Garofalo,
1989

N/A

8-29.8 µg/mL (uptake
anaerobically),
No uptake during
aerobic growth

Gilliland,
1985

Cholesterol
Cholesterol

Serum
Cholesterol

"#!

Reference

Table 2. (Continued)

Study

Organism

Solvent/Medium

Substrate

Membrane

Degradation Results

Reference

Rasic,
et al

Str.
Thermophilus,
L. acidophilus,
L. delbrueckii,
Bif. bifidum

Serum,
MRS Broth

Serum
Cholesterol

N/A

59-276 µg/mL (uptake)

Rasic,
1992

MRS Broth +
Tween80

Water-soluble
cholesterol,
Cholesterolphospatidylcho
line micelles

N/A

7-117 µg/mL (uptake),
8-55 µg/mL (uptake)

Noh,
1997

TPY Medium +
taurocholic acid

Serum
Cholesterol

N/A

6-50% removal

Tahri,
1996

TPY Medium +
oxgall

Serum
Cholesterol

N/A

MRS Medium +
bile salts

Serum
Cholesterol

N/A

Noh,
et al

Tahri,
et al
Tahri,
et al

!

L. acidophilus
BB536, ATCC
15697/15700/1
5698/25527/25
525/25910/259
12/25911
BB536,
ATCC15700/
25527

Lin, et al

L. acidophilus

Strauss

N/A (Enzyme
mix)

Serum

Collagen

"#!

N/A

0-3% removal (resting
cells),
22-42% (growing cells)
20-57% removal (oxgall),
43-71% (cholic acid),
11-52% (taurocholic acid)
N/A

Tahri,
1995
Lin,
2000
Medical
Breakthroughs,
2011

It was found that a maximum of 31% of total cholesterol was removed. Immobilized
bacteria were shown to have the greatest rates of cholesterol removal within 48 hours of
incubation.
ATCC 25544 was used for cholesterol degradation experiments for aqueous
dispersion of cholesterol and cholesterol embedded in liposomes (Goetschel, 1992). 33%
of cholesterol that was dispersed in aqueous medium had undergone conversion after 24
hours of incubation. In the case of cholesterol liposomes, 98% was converted after 16
hours. Garofalo, et al studied the use of P. pictorum encapsulated in open pore agar
beads and alginate-poly-l-lysine capsules for cholesterol degradation (Garofalo, 1989).
As indicated by their results, about 50% of cholesterol was degraded by immobilized
bacteria as opposed to 25% by free bacteria.
Gilliland, et al (Gilliland, 1985) studied serum cholesterol removal of various
strains of L. acidophilus, including GP1B, GP4A, RP43, RP32, C1-5, C2-5, GP2B, P47,
and S-1. It was shown that strains C1-5, C2-5, GP2B, and P47 had low cholesterol
removal with the lowest removal of about 5 µg/mL.
Rasic, et al (Rasic, 1992) studied the serum cholesterol assimilation of L.
delbrueckii subsp. bulgaricus (LB1, LB2, LB3), Str. thermophilus (T1, T2), Bif. bifidum
(BYU, BPO), yoghurt culture (Jog.), and L. acidophilus (AP, AM, AD). LB1 was shown
to have the highest assimilation of 276 µg/mL over a time period of 20 hours.
Tahri, et al (Tahri, 1996) showed that strains BB536, ATCC 15697, 15700,
15698, 25527, 25525, 25910, 25912, and 25911 were able to deplete 40-61% of serum
cholesterol over a 24-hour time period. In another study by Tahri, et al (Tahri, 1995),
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bacterial strains BB536, ATCC 15700 and 25527 were used to study serum cholesterol
assimilation in the presence of bile salts. It was shown that ATCC 15700 had the highest
assimilation of 60%. It was stated by the authors that the bile salts led to significant
assimilation.
Meei-Yn Lin, et al (Lin, 2000) studied serum cholesterol degradation using
several strains of Lactobacillus acidophilus (ATCC 4356, B, E, Farr, LA-1, and N-1) in
the presence of different bile salts (oxgall, cholic acid, and taurocholic acid). The
combination of strain and bile salt that resulted in the highest degradation ability of about
71% over a 24-hour duration was that of ATCC 4356 and cholic acid.
Noh, et al (Noh, 1997) showed that L. acidophilus ATCC 43121 supplemented
with 92 µg/mL water-soluble cholesterol and oxgall had assimilated 44 µg/mL during
growth. When Tween 80 was added, the assimilation was 117 µg/mL. Cholesterolphospatidylcholine micelles (III-E, III-S, Dioleoyl, Distearoyl) were also studied, and it
was shown that the Dioleoyl type had the highest assimilation of 47 µg/mL. When
Tween 80 was added to the micelles, the assimilation was 55 µg/mL.
The most recent and unique study that is still under development by Strauss
(Medical Breakthroughs, 2011) is that of a “Liquid Drano,” which consists of an enzyme
mix that degrades mostly collagen present within atherosclerotic plaque.
2.6 Cholesterol Degradation Rate
Kinetics of cholesterol degradation of free and immobilized bacteria will be
compared. Cholesterol degradation rates will be expressed in the form of the rate
equation used to correlate reaction rate with concentration of the reactant species in a
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chemical reaction (Ebbing, 2010). In previous research performed by Salva, et al, it was
found that cholesterol oxidase from Brevibacterium sp. exhibited a first order reaction
rate (Salva, 1999). Assume the reaction shown in Eqn. 7. The cholesterol degradation
rate, r, is given by Eqn. 8:
!!!!!

(7)

!

(8)

!!! !

where k is the rate constant of reaction, [A] is the cholesterol concentration and n is the
reaction order.
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3.0 RESEARCH OBJECTIVES!
The objectives of this research effort were three-fold:
3.1 The first objective was to optimize the growth medium for non-immobilized R.
erythropolis (ATCC 25544) in order to minimize the production of the trehalose
biosurfactant.
3.2 The second objective was to devise extraction methods to enable biosurfactant and
cholesterol quantification for free and immobilized R. erythropolis.
3.3 The third objective was to assess the effect of capsule miniaturization on cholesterol
degradation rates supported by statistical significance testing.
Much research has been conducted on the use of microencapsulation technology
and bacterium for cholesterol degradation, as documented in the Literature Review
section. To date, no cholesterol degradation studies have been performed on
Rhodococcus erythropolis (ATCC 25544) encapsulated in Ca-alginate beads.
Additionally, no characterization has been performed on the miniaturization of the
capsules immobilizing the bacteria. Most studies in the literature have dealt with
extraction of cholesterol oxidase produced by bacteria followed by cholesterol
degradation. Furthermore, the effects of glycolipid biosurfactant synthesis on the
encapsulated bacterial growth and activity have not been documented in the literature.
Since ATCC 25544 has been shown to degrade cholesterol at a high rate (Bianchi, 1996),
it has been chosen as the strain for this research effort.
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4.0 MATERIALS AND METHODS!
Described in this chapter are the methodologies undertaken in this research effort.
Shown in Fig. 6 is the roadmap of this research study from start to finish.

!
Figure 6. Roadmap of research study.
4.1 Materials!
4.1.1 Bacterial Cell Culture!
Rhodococcus erythropolis (ATCC 25544) and LB growth medium were obtained
from the American Type Culture Collection (ATCC). Cholesterol powder of 95% purity
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was obtained from Sigma Aldrich (C7529-25G). Chemicals used for cell immobilization
were obtained from Sigma Aldrich.
An incubator (Heraeus) with CO2 gas was used for all bacterial cultures at 37°C.
All materials (excluding the bacterium) used in this study were sterilized using an
autoclave (TOMY SS-320) in order to prevent contamination of live bacterial cell
cultures. Prior to experimentation, liquids were further sterilized using a sterile Millipore
luer-lock, fitted filter attached to a 30-mL syringe.
Bacterial cell count measurements were carried out on CELL-VU® CBC
disposable hemacytometers (Millenium Sciences, Inc.) under a Nikon Eclipse Ti-S
microscope with an attached Andor Technologies camera.
4.1.2 Preparation of LB Broth Medium!
LB Broth was prepared according to ATCC’s instructions. The contents of one
packet were emptied into a clean autoclaved 1000-mL capped glass bottle to which 500
mL sterile DI water was added. The bottle was loosely capped and autoclaved. Once
autoclaved, the bottle was allowed to cool to room temperature with the cap was tightly
fastened, and stored in a refrigerator at 4°C.
4.1.3 Preparation of 1X PBS!
1X PBS was prepared by mixing 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g
KH2PO4 with 800 mL DI water in a sterile clean 1000-mL capped glass bottle. The pH
was adjusted to 7.4 by adding enough NaOH as necessary. The acidity was monitored
continuously with a pH electrode while adding NaOH. Once the pH was adjusted to 7.4,
the total volume of the solution was made to 1000 mL by adding enough DI water as
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necessary. The bottle was then autoclaved. Once autoclaved, the bottle was allowed to
cool to room temperature with the cap was tightly fastened, and stored in a refrigerator at
4°C.
4.1.4 Preparation of 3% (w/v) Sodium Citrate !
A 3% (w/v) sodium citrate was prepared by mixing 3 g sodium citrate dihydrate
with 100 mL DI water in a sterile clean 200-mL glass beaker. Once fully mixed, the
solution was filter sterilized into a sterile Falcon® tube, which was capped tightly and
stored in the refrigerator at 4°C.
4.1.5 Quantification Assays!
Assay quantification and optical density measurements were carried out using an
Agilent 8453 UV-Vis Spectrophotometer. Plastic cuvettes (FisherBrand, methacrylate,
1.5-mL, 13-mm path length) were used for all measurements carried out in the visible
range. Quartz micro cuvettes (Agilent Ultra Micro 50, Part No. 5062-2496) were used
for all measurements of samples containing organic solvents.
The chemicals used for the glycolipid assay were obtained from SJSU and
consisted of anthrone (Metheson Coleman and Bell), 12.1M hydrochloric acid (HCl),
concentrated sulfuric acid (H2SO4), chloroform (CHCl3), methanol (CH3OH), and
acetone. Cholesterol assays were performed using a cholesterol quantitation kit from
Abcam (Abcam ab65359). The contents of the Abcam assay kit consisted of all
necessary reagents, namely cholesterol standard, cholesterol assay buffer, enzyme mix,
cholesterol esterase, and cholesterol probe.
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4.1.6 Software!
The camera software used for size measurements was NIS Elements BR 3. Data
analysis for the design of experiment (DOE) and standard formulae were validated using
Minitab 16. A MicroFab JetServer was used for inkjet bioprinting of capsules. Microsoft
Excel 2011 was used to plot all assay data, calibration curves, and concentration profiles.
4.2 Bacterial Growth Medium Optimization
4.2.1 Challenge with Bacterial Growth Measurements!
Bacterial growth measurements were conducted for free and encapsulated bacteria
in a growth medium composition of LB Broth and BSA as described in Section 4.3. The
corresponding growth curves are shown in Fig. 7. The growth curve of free bacteria is
shown in blue, and the growth curve of encapsulated bacteria is shown in red.
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Figure 7. Growth curve of free (shown in blue) and encapsulated bacteria (shown in red)
in regular growth medium (LB and BSA).
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After 200 h of incubation, measurements of bacterial growth in the encapsulated
case were impossible to perform due to the presence of a glycolipid biosurfactant that
breached the capsule membrane as detected visually under the microscope. Refer to Fig.
31 in Section 5.4.
4.2.2 Design of Experiments (DOE) using Taguchi Screening Designs
In this research, the technique of Design of Experiments (DOE), specifically
Taguchi designs, was used to optimize the growth medium composition in order to
minimize the production of bio-surfactant (response 1) and monitor growth (response 2).
Taguchi designs are modified orthogonal arrays for robust screening and optimization of
operating parameters (Roy, 2001). The type of optimization used was Nominal the Best
with a target amount of biosurfactant produced of 0 mg. The formulae needed to conduct
the optimization based on the Sensitivity (Sm) Signal to noise ratios (S/N), Difference
(D) and Rank (R) for the Nominal the Best Optimization types are given by Eqns. 9-12
(Roy, 2001).
! !!

!!!

! !!!!"!
!

(9)

where D is the difference, i is the element corresponding to the level, j is the element
corresponding to the factor, S/N (dB) is the signal-to-noise ratio in dB, and L is the total
number of levels.
! ! !"#$%&% !! ! !"#"$%$!!! !
where R is the rank and nk is the value of response for the k-th response value.
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(10)
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where S/N (dB) is the signal-to-noise ratio in dB, ! is the mean of response data, nk is the
value of response for the k-th response value, and N is the total number of replications.
!" !" ! !" !"#!"

! !!

!

(12)

!

where Sm (dB) is the sensitivity in dB, nk is the value of response for the k-th response
value, and N is the total number of replications.
The optimal operating level by parameter is determined by ranking the
importance of each factor based on averaged (Sm) and (S/N) as conducted in the case of
an ANOVA for traditional orthogonal array analysis. The ranking scale is an attribute
scale ranging from one to a maximum possible value equal to the number of factors in the
experimental matrix. As the difference (D) increases, the ranking (R) increases.
An L16 Taguchi screening design matrix was conducted (Roy, 2001) according to
the layout in Table 3 with 5 factors [LB Broth (in % vol), BSA (in % vol), PBS (in %
vol), temperature (in ˚C), and cholesterol concentration (in mg/mL)] and 4 levels for a
48-hr growth monitoring study period. The experiments in Table 3 were conducted in
duplicate. Optimization types by response are shown in Table 4.
Following manual calculations and response plot generation for the Sm and S/N
quantities, the results were validated graphically using Minitab 16. The expanded
experimental matrix is shown in Table 5. The concentration at which cholesterol was
centered was the high-risk blood cholesterol level of 2 mg/mL (Tahri, 1995).
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Table 3. L16 Taguchi design (N = 2).
No
1
2
3
4
5

Variables
BSA (% vol)
LB (% vol)
1X PBS (% vol)
CHOL (mg/ml)
TEMP (°C)

Levels
0, 6.6, 13.2, 20.0
0, 13.2, 26, 40
0, 13.2, 26, 40
0, 13.2, 26, 40
4, 23, 30, 37

!
Table 4. Optimizations type by response.
Responses
Bacterial growth
Amount of bio-surfactant produced

Type of Optimization
Nominal the best
(Target = unknown)
Nominal the best (Target = 0)

!
!
!
Table 5. L16 (5 variables, 4 levels) Taguchi matrix for biosurfactant minimization.

!

No.

BSA
(% vol)

LB
(% vol)

PBS
(% vol)

Cholesterol
(mg/mL)

Temperature
(°C)

Bacteria
(%vol)

1

0.0

0.0

0.0

0

4

5.00

2

0.0

13.2

13.2

3

23

5.00

3

0.0

26.0

26.0

6

30

5.00

4

0.0

40.0

40.0

9

37

5.00

5

6.6

0.0

13.2

6

37

5.00

6

6.6

13.2

0.0

9

30

5.00

7

6.6

26.0

40.0

0

23

5.00

8

6.6

40.0

26.0

3

4

5.00

9

13.2

0.0

26.0

9

23

5.00

10

13.2

13.2

40.0

6

4

5.00

11

13.2

26.0

0.0

3

37

5.00

12

13.2

40.0

13.2

0

30

5.00

13

20.0

0.0

40.0

3

30

5.00

14

20.0

13.2

26.0

0

37

5.00

15

20.0

26.0

13.2

9

4

5.00

16

20.0

40.0

0.0

6

23

5.00
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4.2.3 Experimental Protocol!
An experimental flow diagram of bacteria growth measurements for
microencapsulated bacteria is shown below in Fig. 8. In short, equal volumes of
chloroform:methanol (2:1, v/v) were added to the culture vial, and the vial was shaken
vigorously. The contents were filtered through a 100-micron nylon mesh cell strainer in
order to separate the microcapsules from the culture broth. The microcapsules were
rinsed with 3 mL acetone followed by 3 mL DI water. The acetone and DI water were
retained. The microcapsules and culture broth had undergone specific protocols, outlined
below, in order to obtain growth measurements and glycolipid quantification,
respectively.
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!
Figure 8a. Experimental flow diagram for biosurfactant quantification and bacteria
growth measurements.
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Figure 8b. Experimental flow diagram for cholesterol quantification.
4.2.3.1 Protocol for Growth Measurement !
The microcapsules were removed from the filter and placed into a 20 mL glass
scintillation vial. 4 mL of 3% (w/v) sodium citrate solution were added to the vial. The
vial was then capped and vortexed in order to dissolve the capsules. The contents in the
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vial were transferred into 1.5-mL Eppendorf tubes and then centrifuged at 8,000 rpm for
5 min to separate the bacteria from the liquid. After centrifugation was complete, the
supernatant in each tube was removed, thus leaving behind the bacteria pellet. Each
pellet was transferred into a fresh clean tube with 1.5 mL of fresh LB Broth and vortexed
until the pellets were fully dissolved. After 2X dilution, the bacterial solution was placed
in a plastic cuvette for spectrophotometric measurement of %transmittance at a
wavelength of 600 nm using fresh LB Broth as a control.
4.2.3.2 Glycolipid Extraction and Quantification!
Ristau, et al’s (Ristau, 1983) method of glycolipid extraction was used. A
chloroform:methanol (2:1, v/v) was added in equal volume to the bacterial culture,
shaken vigorously, and allowed to sit in order for the layers to separate. This resulted in
a biphasic separation in which case the glycolipid was sandwiched in between the organic
phase (bottom) and aqueous phase (top) as shown in Fig. 9. In Fig. 9, the aqueous phase
was stained with blue dextran for visualization purposes.
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Figure 9. Biphasic separation of glycolipid biosurfactant.!
The organic phase consisted of chloroform and cholesterol while the aqueous
phase consisted of the bacteria, culture broth, and methanol (Ristau, 1983). The organic
phase was decanted and discarded into a waste container. 1 mL of distilled water was
added to the remaining glycolipid precipitate and vortexed until dissolved. 0.5 mL of
each glycolipid precipitate was transferred into separate 40-mL glass scintillation vials
and subsequently mixed with 0.5 mL DI water. Each sample was then quantified using
the Anthrone assay method.
The culture broth was transferred into 1.5 mL Eppendorf tubes and centrifuged at
8,000 rpm for 3 min in order to separate the glycolipid from the liquid. After
centrifugation, the aqueous and organic phases were removed, thus leaving behind the
glycolipid precipitate. All glycolipid precipitates were transferred into a clean tube with
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1 mL DI water. These samples were then subject to the Anthrone assay for quantification
of glycolipid as outlined in Section 4.2.1.2.1.
The Anthrone assay (Ristau, 1983) was used to quantify glycolipids by measuring
the carbohydrate content present in the sugar moieties. The assay mechanism (Nigam,
2007) is shown in Fig. 10. Hydrochloric acid (HCl) serves to dehydrate the carbohydrate
into a compound known as furfural, which condenses with Anthrone to form a green
color, the intensity of which is proportional to the amount of carbohydrate in the sample.
The intensity of the color is measured through the peak height of the absorbance at a
wavelength of 620 nm. The assay was calibrated against glucose standard using the
following volumetric measurements outlined in Table 6.

Figure 10. Chemical Principle of Anthrone Assay.!
Table 6. Volumetric measurements for set-up of calibration curve for anthrone assay.!

Vial#

Concentration
(mg/mL)

1
2
3
4
5
6

0
20
40
60
80
100

VStock Solution
(mL)

VDI Water
(mL)

0.0
0.2
0.4
0.6
0.8
1.0

1.0
0.8
0.6
0.4
0.2
0.0

1.0 mL of each concentration was transferred into separate 40-mL glass
scintillation vials in triplicate and placed in a laminar flow hood. 2 mL of concentrated
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HCl were added to each vial, which was placed in a boiling water bath for three hours. 4
mL of 0.2% (w/v) anthrone solution dissolved in cold H2SO4 were added to each vial
slowly and carefully. The vials were then placed into a boiling water bath at 100°C for
15 min. Once complete, the vials were removed from the water bath and kept in the
laminar flow hood to cool down and allow the resulting vapor to vent. Once cooled
down to room temperature (23°C), a 1.5 mL volume of the contents was transferred into a
plastic cuvette for optical density spectrophotometric measurements at a wavelength of
620 nm using DI water as a control. The peak heights of the absorbance spectra at 620
nm were plotted against the sample concentrations to yield a calibration curve.
4.3 Growth Curve of Free and Encapsulated Bacteria
4.3.1 Free Bacteria
Growth measurements were setup with the optimized medium. Samples were
taken every 24 hours and subsequently diluted 10X prior to absorbance peak height and
%transmittance measurements using fresh LB Broth as a control. Next, 0.10 mL of each
sample were pipetted into a disposable hemacytometer (Fig. 11), allowed to sit for 3 min,
and taken to a Nikon Eclipse Ti-S microscope for a cell count (Fig. 12). Cell count
measurements were taken at five locations, which are circled in red in Fig. 11, and then
averaged to obtain a cell count.
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Figure 11. Cell counting chambers of cbc hemacytometer (drawing not to scale).
chambers circled at regions where used for cell counting.

Figure 12. Cell counting chamber of a cbc hemacytometer with live bacteria cells.
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The cell count measurements were then divided by the individual volumes of the
selected chambers to obtain a cell concentration value in number of cells per mL of
culture. The cell concentration was multiplied by the total volume of sample to obtain
the total cell number, which was plotted against the peak heights of the absorbance to
construct a calibration curve.
4.3.2 Encapsulated Bacteria!
Encapsulated bacteria were created using the atomization technique. As
described in Section 4.4, 20 autoclaved 40-mL glass scintillation vials were set up in
triplicate with 5 mL of optimized medium. Growth measurements were carried out in the
same manner as in Section 4.2.2.1. Cell counts were measured, and the growth curve was
constructed in the same manner as in Section 4.2.4.2.1.
4.3.3 Bacterial Growth Curve!
Total bacteria cell number for free and atomized bacteria was plotted against time
(in days) in order to construct the bacteria growth curve.
4.3.3.1 Free Bacteria!
A 1 mL of stock bacterial culture was added to 75 mL LB broth and 1 mL BSA in
a clean autoclaved 125-mL Erlenmeyer flask. The flask was then loosely capped and
placed in an incubator at 37°C. Samples were taken every 24 h starting from the initial
inoculation. Each sample was diluted 10x in fresh LB broth and vigorously mixed for 20
s using a vortex. Once mixed, the contents were transferred to a disposable plastic
cuvette. Peak height absorbance and % transmittance measurements were taken at a
wavelength of 600 nm using fresh LB Broth as a control.
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4.3.3.2 Encapsulated Bacteria
The same growth medium from Section 4.2.1 was used for encapsulated bacteria.
Encapsulated bacteria were placed in autoclaved 40-mL glass scintillation vials in order
to be set up for destructive sampling. Growth medium was added to each vial in a ratio of
(75:1, v/v) LB Broth to BSA.
The capsules were filtered using a 100-µm nylon filter and placed into a 20 mL
glass scintillation vial. 4 mL of 3% (w/v) sodium citrate solution were added to the vial.
The vial was then capped and vortexed in order to dissolve the capsules. The contents in
the vial were transferred into 1.5-mL Eppendorf tubes and then centrifuged at 8,000 rpm
for 5 min to separate the bacteria from the liquid. After centrifugation was complete, the
supernatant in each tube was removed, thus leaving behind the bacteria pellet. Each
pellet was transferred into a fresh clean tube with 1.5 mL of fresh LB Broth. The tubes
were vortexed until the pellets were fully dissolved. After 10X dilution, the bacterial
solution was placed in a plastic cuvette for spectrophotometric measurement at a
wavelength of 600 nm using fresh LB Broth as a control.
4.4 Encapsulation of Bacteria via Atomization and Inkjet Bioprinting
4.4.1 Atomization!
Bacteria were immobilized by atomization according to the procedure described
in (Garofalo, 1989). 3% (w/v) alginate was prepared by mixing 3 g of medium viscosity
alginic acid with 100 mL sterile 0.9% NaCl in a capped 150-mL Erlenmeyer glass flask
on a stirring plate for 24 h. Once fully mixed, the flask was autoclaved and allowed to
cool to room temperature. Next, 1 mL of bacteria culture was placed into a 1.5-mL
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Eppendorf centrifuge tube and centrifuged at 8,000 rpm for 5 min. The supernatant from
the tube was discarded, and the resulting bacteria pellet was rinsed with DI water by
vortexing and subsequently centrifuging. This process was repeated three times. The
pellet was then transferred into the freshly prepared autoclaved alginate and then mixed
for 30 min.
The bacteria-alginate solution was withdrawn into a sterile 10-mL syringe, which
was then connected to the atomization needle attached to a N2 source. The syringeneedle assembly was placed into the syringe pump slot and fixated by actuating the lever.
The atomization needle tip was oriented toward a 50-mL beaker containing 20 mL
sterilized 1.5% CaCl2 and situated on a stirring plate (Fig. 13). An extrusion rate of 0.50
mL/min was selected on the front panel of the syringe pump. The N2 source was
switched on, and the rate of airflow through the atomization needle was set to 12
mL/min.
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Figure 13. Experimental setup for alginate bead fabrication!"
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4.4.2 Inkjet Bioprinting!
Bacteria were immobilized by inkjet printing according to the procedure
described in (Mobed-Miremadi, 2011). Shown in Fig. 14 is a picture of the physical setup of the inkjet printing scheme. Microcapsules were fabricated using the Microfab’s
Jetlab

Figure 14. Set-up of inkjet printing scheme.!
System based on the modification of a previously established method, specifically with
the addition of a physical adsorption step previously established methodology (MobedMiremadi, 2011). The apparatus consisted of a CCD camera (30 fps), a control unit, a
printhead, a triggering unit, a fluid delivery unit, and a PC equipped with proprietary
software (MicroFab JetServer) to tune the bio-ink formulation to the jetting parameters.
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The printhead had an aperture of 60 !m and was rated for !=40 cP and != 72 dyn/cm.
After inputting the jetting variable settings, droplet generation began with the triggering
box sending electrical signals to the inkjet control unit and to the CCD camera control
PC, simultaneously. The inkjet engine fired the 0.5% (w/v) filter-sterilized low viscosity
sodium alginate solution [!=5 cP, != 43 dyn/cm] mixed with bacteria (1 ml centrifuged
bacteria/ml of alginate), into a 15% (w/v) CaCl2 receiving solution. The beads were
allowed to cross-link for 30 min. Following the cross-linking step, 1% (w/v) low
viscosity chitosan was added into the receiving solution to make the final chitosan
concentration 0.5% (w/v). This physical adsorption step was carried out for 30 min at
room temperature using stirring was necessary to confer mechanical strength to the
suspension during the subsequent concentration and centrifugation steps. The capsules
were then centrifuged at 8,000 rpm for 5 min and washed with a 0.9% (w/v) NaCl
solution 3 times.
The source of N2 gas was turned on, and the airflow was set to 20 psi. The
printhead underwent rinses with isopropyl alcohol, DI water, and 0.9% NaCl, each
performed three times and in series in that order. The printhead was rinsed by first filling
the syringe with the appropriate liquid and then setting the 1st knob on the inkjet printer to
“ON” and “PURGE.” Any clogs that were present in the printhead were mitigated by
connecting the tubing output from the syringe directly onto the print head and manually
purging it with 0.9% NaCl. Once rinsing and any clogs were completed, 5-mL bacteriaalginate mixture was put into the syringe. Input parameters shown in Fig. 15 were
entered in the MicroFab JetServer™ software.
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Figure 15. Input parameters for inkjet bioprinting system using microfab jetserver ™.!
The “PURGE” setting was enabled and the 1st knob was set to “ON.” The
vacuum pump was then switched on and set to 25 psi. The backpressure was adjusted as
necessary until the meniscus on the print head tip appeared to be flat. The external lamp
was dimmed, and the strobe light was set to 200 µs. “START JETTING” on the software
was then selected, and the voltage was adjusted as necessary until capsules were visible
as shown in Fig. 16. Capsules were jetted for 2 h into a petri dish filled with 7 mL
sterilized 15% CaCl2. After 2 h of jetting, the capsules were allowed to sit in the 15%
CaCl2 solution for 30 min in order to undergo cross-linking. After cross-linking, the
capsules were placed into a sterile Falcon® tube containing 10 mL of 1% (w/v) chitosan
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solution and allowed to sit for 30 min in order to be coated. After coating was complete,
the contents of the tube were transferred into 1.5-mL Eppendorf centrifuge tubes, capped,
and centrifuged at 8,000 rpm for 3 min. Once centrifugation was complete, the
supernatant solution from each tube was discarded, and the capsules were consolidated
into a single 1.5-mL Eppendorf centrifuge tube to which 1-mL 0.9% NaCl was added.

Figure 16. Close-up view of inkjet printhead ejecting encapsulated bacteria.
4.4.3 Encapsulation Efficiency!
An encapsulation efficiency experiment was conducted in order to understand
how many of the initial cells mixed in the alginate were retained in the capsules after
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crosslinking. In order to do so, 1 mL of a known concentration of bacteria infused in
alginate was atomized into microcapsules using the procedure from Section 4.2.2. The
capsules were then placed in an autoclaved 20-mL glass scintillation vial. 4 mL of 3%
(w/v) sodium citrate was added to dissolve the capsules. The vial was then capped tightly
and vortexed until the capsules were fully dissolved. The contents of the vial were then
added into 1.5-mL Eppendorf centrifuge tubes, which were then centrifuged at 8,000 rpm
for 5 min. The supernatant was then discarded, and the resulting bacteria pellets were
collected into a single fresh falcon tube in which they were re-suspended in fresh LB
Broth, then vortexed until fully dissolved. The absorbance of the bacteria was measured
by way of spectrophotometry at a wavelength of 600 nm using fresh LB Broth as a
control. The peak absorbance value was recorded and, the total cell number was
calculated by way of the calibration curve in Section 5.1.1. Eqn. 13 was used to
determine encapsulation efficiency:
!!!""#$#%&$' ! !

!"#!"!!"##!!"#$%!!"#$%!!"##$%&"'(!!"#$%&'$
!!!!""#
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(13)

4.5 Cholesterol Degradation Experiments
Cholesterol degradation experiments were conducted in three different scenarios:
1. Free bacteria in optimized medium,
2. Encapsulated bacteria via atomization, and
3. Encapsulated bacteria via inkjet bioprinting.
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The purpose of these experiments was to study the effects of miniaturization on
cholesterol degradation. The effects of cell number on cholesterol degradation were also
studied.
4.5.1 Experimental Set-up!
The cell counts from the lag, log, and peak growth were chosen from the bacteria
growth curve in Section 5.1. To obtain the cell counts at those regions, 1.5 mL aliquots
of fresh bacteria culture were first diluted in fresh LB Broth. Peak absorbance values
were measured at 600 nm using fresh LB Broth as a control. The cell count was
calculated and verified using the calibration curve. The cells were then placed in 1.5 mL
Eppendorf tubes and centrifuged at 8,000 rpm for 4 min. Once complete, the supernatant
liquids were discarded, and 1.5 mL sterile DI water were added to each tube, which was
then capped and vortexed for 20 sec to re-suspend the cells. The tubes were then
centrifuged again at 8,000 rpm. The process of washing the cells with DI water was
repeated for a total of three washes in order to ensure no remnants from the previous
growth medium were present.
For the case of cholesterol degradation by free bacteria, the cells were suspended
in 2 mL fresh LB by vortexing for 1 min. The cells were then transferred to autoclaved
40-mL scintillation glass vials and set up in triplicate as outlined in Table 7.
Table 7. Set-up parameters of cholesterol degradation experiment (N = 3).
Phase on Growth Curve from which
Cell Count was Selected
Lag (Nlow = 4.53 x 108)
Log (Nmed = 6.90 x 108)
Stationary (Nhigh = 1.76 x 109)
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Incubation Time (days)
2
2
2

5
5
5

8
8
8

The specified cell counts in Table 7 were harvested and mixed into multiple fresh
autoclaved alginate mixtures, one per vial, which were then subjected to encapsulation.
Bacteria were encapsulated via atomization in the same manner as described in Section
4.2.2. For inkjet bacteria, the low cell count was used. All samples for atomized and
inkjet bacteria were set up in triplicate.
4.5.2 Cholesterol Layer Identification!
The phase in which cholesterol was to be extracted was determined through
Salkowski’s reaction (Romley, 1903). The principle of Salkowski’s reaction is that the
double bond in cholesterol reacts with concentrated sulfuric acid to give bicholestadien
disulphonate, which is pink to dark magenta in color. Shown in Fig. 18 is a series of
glass test tubes filled with different mixtures of solutions and the phase in which
cholesterol was present. As described in Salkowski’s reaction, reaction of cholesterol
with H2SO4 caused the cholesterol to appear pink to dark magenta in color. When H2SO4
was added to cholesterol dissolved in chloroform, the chloroform layer appeared
magenta, indicating that cholesterol was present in that layer. When chloroform and
H2SO4 were added to whole culture broth, encapsulated bacteria, and cholesterol, the
chloroform layer once again appeared magenta in color, thereby confirming that the
cholesterol was consistently present within that layer. Hence, cholesterol extraction was
performed from the chloroform phase.
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Figure 17. Cholesterol phase identification using salkowski’s method (1-cholesterol
powder, 2-sulfuric acid, 3-chloroform, 4-culture broth, 5-capsules, 6-methanol, 7-water).!

4.5.3 Cholesterol Quantification!
Quantification of cholesterol was carried out by way of a colorimetric assay kit
from Abcam. The Abcam assay kit utilizes the mechanism of cholesterol quantification
as follows. In summary, cholesterol reacts with cholesterol oxidase enzyme in the
presence of O2 to produce 4-cholesten-3-one and H2O2. H2O2 reacts with the provided
cholesterol probe to produce resorufin, which is pink in color. The intensity of the pink
color is proportional to the amount of cholesterol present in solution. The intensity was
measured through the peak values of the absorbance at a wavelength of 570 nm.
All contents of the assay were warmed to room temperature in a shaker until
thawed. The vials containing cholesterol esterase and enzyme mix were each dissolved
in 220 µL of cholesterol assay buffer. A 0.25 µg/µL stock solution of cholesterol
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standard was prepared by mixing 20 µL of cholesterol standard with 140 µL cholesterol
assay buffer and vortexing for 1 min. A calibration curve was constructed by adding the
volumes of cholesterol standard and cholesterol assay buffer outlined in Table 8 into a
series of 1.5 mL Eppendorf centrifuge tubes, which were labeled accordingly.
Table 8. Volumetric measurements of set-up for calibration curve of abcam cholesterol
assay.
!
Tube #

Mass of
Cholesterol (µg)

VCholesterol Standard
(µL)

VCholesterol Assay Buffer
(µL)

1
2
3
4
5
6

0
1
2
3
4
5

0
4
8
12
16
20

50
46
42
38
34
30

The reaction mix was prepared by adding 44 µL cholesterol assay buffer, 2 µL
cholesterol probe, 2 µL enzyme mix, and 2 µL cholesterol esterase into a 1.5 mL
Eppendorf centrifuge tube and vortexing for 1 min. Enough reaction mix was prepared
such that there were 50 µL per sample being assayed. 50 µL of reaction mix was added to
each tube and vortexed for 10 sec. After mixing, the tubes were placed in the incubator
at 37°C for 60 min. Once incubation was complete, the tubes were removed from the
incubator and vortexed. Optical density spectrophotometric measurements were
conducted in the quartz glass cuvette at 620 nm using 100 µL cholesterol assay buffer as
a control sample. The peak absorbance values were recorded. Samples were diluted with
cholesterol assay buffer as necessary in order to keep the absorbance at a maximum value
of 1.0.
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5.0 RESULTS
5.1 Growth medium Optimization and Validation
5.1.1 Optimization
Shown in Fig. 18 is the Sm plot for glycolipid biosurfactant production after 48 h
of incubation for BSA, LB, PBS, Cholesterol, and Temperature. The amounts of
biosurfactant are represented by the y-axes. The corresponding S/N plots for
biosurfactant production are shown in Fig. 19. Similarly, the Sm and S/N plots for
bacterial growth, with y-axes for all Sensitivity plots representing the %T are presented in
Figs. 20 and 21, respectively. The analyses for biosurfactant production and bacterial
growth are presented in Tables 9 and 10. The raw data for both responses are tabulated in

Sm (dB)

Appendix B.
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Figure 18. Sensitivity plot for BSA, LB, PBS, cholesterol, and temperature on
biosurfactant production.
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Figure 19. Signal-to-noise ratio plot for BSA, LB, PBS, cholesterol, and temperature on
biosurfactant production.
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Figure 20. Sensitivity plot for BSA, LB, PBS, cholesterol, and temperature on bacteria
growth.
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Figure 21. Signal-to-noise ratio plot for BSA, LB, PBS, cholesterol, and temperature on
bacteria growth.
!
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Table 9. Summary of Taguchi analysis of biosurfactant production using the nominal the best optimization type.

Variable

Delta

Rank

BSA
LB
PBS
CHOL
TEMP

210
305
600
597
575

5
4
1
2
3

Optimal
Level
Based
on Sm
2
4
2
1
1

Delta

Rank

3.54
10.0
8.11
9.14
7.31

5
1
3
2
4

Optimal
Level
Based
on S/N
4
2
2
1
2

Theoretical
Optimal
Level of
Operation
2
2
2
1
1

Selected
Level of
Operation
2
2
2
2
4

Table 10. Summary of Taguchi analysis of bacterial growth using the nominal the best optimization type.
Optimal
Level
Variable Delta Rank
Based
on Sm
BSA
1.70
3
3
LB
0.84
4
2
PBS
0.22
5
2
CHOL
2.06
2
1
TEMP
7.99
1
1

!

Delta

Rank

8.63
8.69
6.83
18.4
15.8

4
3
5
1
2

""!

Optimal
Level
Based
on S/N
3
4
1
3
1

Theoretical
Optimal
Level of
Operation
3
4
1
3
1

Selected
Level of
Operation
2
2
2
2
4

5.1.2 Validation using Minitab
Shown in Figs. 22 and 23 are the main effects plot for means and signal-to-noise
ratios for biosurfactant at 48 h, respectively. As can be seen, the trends are identical to
the data presented in Figs. 18 and 19. Hence, the optimization method using Excel was
validated.

Figure 22. Main effects plot for means of glycolipid biosurfactant for t = 48 h.
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Figure 23. Main effects plot for signal-to-noise ratios of glycolipid biosurfactant for t =
48 h.!
5.2 Bacteria Growth Study
5.2.1 Calibration Curve!
The triplicated calibration curve of bacteria cell number (N) determined by the
CBC hemacytometer is related to the optical density (OD) at 600 nm (Fig. 24) and is
given by Eqn. 14:
!"##!!"#$%& ! ! !!!"! !"!!""!!"! ! !!!"! .
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3.50E+09

y = 6E+09x - 8E+07
R! = 0.97611

3.00E+09
2.50E+09

N

2.00E+09
1.50E+09
1.00E+09
5.00E+08
0.00E+00
$%$$&'$$! (%$$&)$(! *%$$&)$(! +%$$&)$(! ,%$$&)$(! "%$$&)$(!
-5.00E+08
OD (600 nm)

Figure 24. Calibration curve of bacterial cell count in optimized medium.!
5.2.2 Encapsulation Efficiency
It was determined that 86.2% of the cells that mixed into the alginate mixture
prior to atomization were immobilized within the capsules. The encapsulation efficiency
for the inkjet bacteria is not available since the methodology has not been developed to
date.
5.2.3 Growth Curve!
5.2.3.1 Growth Curves Prior to Growth Medium Optimization!
Shown in Fig. 25 is the growth curve of free bacteria (blue) and encapsulated
bacteria (red) in regular growth medium, which consisted of LB Broth and BSA. Death
phase begins at 45 h with the bulk of the encapsulated population decimated at 212 h as
compared to the onset of the decay phase occurring at 288 h for the free bacteria.
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Figure 25. Growth curve of free (shown in blue) and encapsulated bacteria (shown in
red) in regular growth medium (LB and BSA).!
It is important to note that bacteria growth was initially conducted in a shaker at
37ºC with the prospect that biosurfactant would emulsify. It was observed, however, that
the bio-surfactant did not emulsify but in fact coalesced with the alginate membrane. In
order to obtain a viable solution for immobilized bacterial growth, the DOE elaborated
upon in the previous section was devised.
5.2.3.2 Growth Curves Post Growth Medium Optimization
Shown in Fig. 26 is the growth curve for free bacteria (red) and encapsulated
bacteria (blue) in optimized growth medium. The regions circled in purple at t = 2, 5, and
8 correspond to the lag phase, log phase, and stationary phase, respectively. As can be
seen, the lag and log phases seem to follow the typical growth behavior. However, the
stationary phase seems to be short-lived. It is important to note that such atypical growth
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behavior is possible since the growth medium was altered in order to minimize the
amount of biosurfactant by-product that is naturally created by the bacteria (Shuler,
2002).
From the calibration curve, total cell numbers were obtained and were plotted
against time for both free and microencapsulated bacteria, thus constituting the bacteria
growth curve shown in Fig. 26. As can be seen for the free bacteria, there was a lag
phase of 3 days, a log phase from 5-7 days, and a peak growth observed at 8 days, which
was the short-lived stationary phase. It can be seen that growth of microencapsulated
bacteria was characterized by a lag compared to that of free bacteria. Such a
characteristic is indicative of the diffusion barrier provided by the alginate membrane.
From the curve, it was inferred that the bacteria were able to survive in the encapsulated
state as a result of growth medium optimization.
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Figure 26. Growth curve of free (shown in red) and encapsulated bacteria (shown in blue) in optimized medium.
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5.3.1 Calibration Curve
Shown in Fig. 27 are the colorimetric products of the anthrone assay when
calibrated against the glucose standard at concentrations of 0-100 mg/mL (left to right).
As the concentration of glucose increases, the color of the reaction gains a darker green
tone. As shown in Fig. 28, the triplicated spectrophotometric calibration curve
correlating absorbance (A) to the glucose standard concentration is linear and given by a
correlation given by Eqn. 15.
!!"# ! !!!!"#! !"#$%#&'(&)"#!!"!!"#$%&'!!"#$%#&%!!!" !"!
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Figure 27. Calibration curve samples of anthrone assay for a glucose concentration range
of 0-100 mg/mL (left to right).
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Figure 28. Calibration curve of anthrone carbohydrate assay against glucose standard.
5.3.2 Glycolipid Profile For Encapsulated Bacteria
Shown in Fig. 29 is the mass profile of glycolipid produced by atomized bacteria
over time. As can be seen, the glycolipid production stabilized after 7 days, thus
confirming the validity of the DOE optimization parameters. The experiment was
performed in duplicate (N = 2) starting from an initial cell count of N = 2.06 x 10 7, and
destructive sampling was employed. An S-Shaped trend is detected with the glycolipid
mass being asymptotic at 50 mg between days 6 and 10 days. It could be observed that
80% of the glycolipid production occurs the first 2 days.
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Figure 29. Mass profile of glycolipid for atomized bacteria.!
5.4 Cholesterol Degradation Studies!
As shown in Fig. 30, microcapsules fabricated by atomization had an average
diameter of 850 ±50 µm and had a thickness of 6 µm. A total of 30 microcapsules were
examined to calculate the dimensional statistics. Shown in Fig. 31 are the encapsulated
bacteria in culture broth at 4X magnification. As can be seen, the glycolipid
biosurfactant and cholesterol powder adsorbed onto the surface of the alginate capsules.
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Figure 30. Atomized bacteria (at 10X) used throughout the study (before experiment).
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Figure 31. Atomized bacteria (at 4X) in culture broth after t = 8 days of incubation
(before extraction).
Shown in Fig. 32 are the same capsules at 10X magnification from Fig. 31 after
treatment with (2:1, v/v) chloroform:methanol. As can be seen, the medium is free of
glycolipid biosurfactant and cholesterol, and the alginate membranes appear to be intact.
Shown in Fig. 33 are the capsules at 20X magnification fabricated by inkjet printing. The
capsule diameter was 32 ± 5 !m based on 30 examined capsules. In comparison to the
atomized capsules (Fig. 30), a lower bacterial cell density can be observed in the inkjet
capsules as presented in Fig. 35. Since the surface area-to-volume ratio increases with
miniaturization, a smaller core volume is available for growth.
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Figure 32. Atomized bacteria (at 10X) after 8 days of incubation (after extraction).

Figure 33. a) Encapsulated bacteria (at 20X) fabricated by way of inkjet printing,
b) magnified bacterial cells (at 60X) within miniaturized capsule (individual cells labeled
with arrows.)
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5.4.1 Cholesterol Quantification
Shown in Fig. 34 is the triplicated calibration curve for the Abcam Cholesterol
Quantitation Kit. The correlation of absorbance (A) regressed against the mass of
cholesterol (µg) is linear and is characterized by the following equation (Eqn. 16):
!!"#!!" ! !!!!"!! !"##!!"!!!!"#$%#&!"! !" !!

(16)
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Figure 34. Calibration curve for abcam cholesterol quantitation kit.
5.4.2 Cholesterol Degradation Profiles!
5.4.2.1 Degradation Rate Calculations!
Shown in Fig. 35 is a sample cholesterol degradation rate plot for atomized
bacteria for an initial cell count of N = 4.53 x 108. As mentioned in the Methods section
destructive sampling was conducted at days 2, 5 and 8 corresponding to the lag, log and
stationary phases of the growth curve presented in Fig 26. Since the bulk of glycolipid
growth occurs within the first 2 days according to Fig. 29, for analytical purposes it will
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be assumed that the 0-2 day interval corresponds to the period of free cholesterol
diffusion (period 1) through the capsule membrane and the 2-8 day period (period 2)
corresponds to the glycolipid-mediated transport period. Although degradation rates for
both periods were analyzed, emphasis was placed on the free diffusion period.
Furthermore since the Stokes’ radius of cholesterol (a = 0.54 nm) is an order of
magnitude smaller than the microcapsules pores (a = 5 nm for atomized and a = 8 nm
for inkjet) (Simpliciano, 2012), diffusion resistance will not be taken into account in rate
calculations. The rate equations, kinetic constants (when applicable) and regression
coefficients for free and immobilized bacteria are presented in Tables 11 and 12.
Table 11. Degradation rates of cholesterol by free, atomized, and inkjet bacteria for the
free diffusion phase at Nlow (4.53 x 108).
Bacteria
Immobilization State
Rate Equation
Zero Order Kinetic
Constant (mg mL-1
day-1)

Free

Atomized

Inkjet

dC/dt =
dC/dt =
-0.1502 [C]0 -0.1109 [C]0
0.1502

0.1109

dC/dt =
-0.6025 [C]0
0.6025

Table 12. Degradation rates of free, atomized, and inkjet bacteria for the glycolipidmediated transport phase at Nlow. (4.53 x 108).
Bacteria
Immobilization
State

Free

Atomized

Inkjet

Rate Equation

dC/dt =
-0.0313 [C]0

dC/dt =
-0.0901 [C]0

dC/dt =
-0.0259 [C]0

Regression
Coefficient

0.933

0.999

0.866
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Since the profiles for both period were linear by design or regression analysis, the
reaction order, n, is equal to zero, thereby rendering them as zero-order equation.
5.4.2.2 Effect of Initial Cell Count on Cholesterol Degradation
Prior to the encapsulation experiments statistical significance testing using a
student t-test (Dalgaard, 2008) was conducted on free bacteria to determine the effect of
initial cell count on cholesterol degradation. In this case, the null hypothesis (H0) was
that there is no significant difference between initial free bacteria cell count and amount
of cholesterol degraded. The alternate hypothesis (H1) was that there would be a
difference in cholesterol concentration as cell number was varied. For all t-test studies,
95% confidence was assumed, thus rendering ! = 0.05. The same followed for the
atomized bacteria (Table 13). Metabolite degradation plots at Nlow (4.53 x 108), N med
(6.90 x 108), and Nhigh (1.76 x109) are presented in Fig. 36. The reduction in the mass of
cholesterol during the 0-2 day period (period 1) was used to conduct the significance
testing. As shown in the graphical trends, more specifically the super-imposition of the
plots and results of the significance testing shown in Table 13, the null hypothesis (H0)
failed to be rejected for all 3 pairwise comparisons because of p-values being greater than
!.
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Figure 35. Normalized cholesterol concentration profile as a function of time for free
bacteria (NLow).
Table 13. Significance testing summary comparing the effect of cell count to cholesterol
degradation for the free bacteria.
Scenario

Nlow vs.
Nmed

Nlow vs.
Nhigh

Nmed vs.
Nhigh

!
T-value
p-value

0.05
-0.55
0.635

0.05
0.24
0.83

0.05
1.65
0.242

5.4.2.3 Cholesterol Degradation for Immobilized Bacteria !
As proven above, since the effect of initial cell count was negligible on
cholesterol degradation rate, it was decided to conduct bacterial immobilization at lower
cell count to prevent nozzle blockage during the jetting portion of the microencapsulation
processes. Metabolite degradation plots at Nlow (4.53 x 108) are presented for the
atomized and inkjet-printed bacteria Fig. 36. The profiles can be described by the same
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two regions used to describe free bacteria behavior. The first is delimited by the 0-2 day
and the second by the 2-8 day time periods. The reduction in the mass of cholesterol
during period 1 was used to conduct the significance testing between the two types of
immobilization methods. The null hypothesis, H0 was that there would be no significant
difference in cholesterol removal at day 2 between the atomized and inkjet-immobilized
bacteria. The alternate hypothesis, H1, was that there would be a difference in cholesterol
removal at day 2 between the atomized and inkjet-immobilized bacteria. As seen in
Table 14, the reduction in capsule diameter has a significant effect on cholesterol
degradation rate.
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1.00
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0.80

Inkjet (period 2)
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Figure 36. Cholesterol degradation profiles for free and immobilized bacteria as a
function of time for Nlow = 4.53 x 108.
!
!
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Table 14. Summary of t-test significance testing for the effect of capsule miniaturization
on cholesterol degradation rates at Nlow = 4.53 x 108.
Scenario

Atomized vs. Inkjet

T-value
p-value
Accepted Hypothesis

5.9
0.028
H1

5.4.2.4 Synopsis of Cholesterol Degradation Results
A synopsis of cholesterol degradation results in terms of percent decrease as a
function of bacterial immobilization state is presented in Table 15. A monotonous
decrease in metabolite was observed for all initial cells counts and immobilization states.
Focusing on the low cell count (Nlow) category, throughout sampling intervals, the
percent decrease was greatest for the inkjet-printed bacteria.
Table 15. Percentage degradation of cholesterol mass for free, atomized, and inkjet
bacteria in optimized medium.
Free Bacteria

Atomized

Inkjet

Time
(days)

NLow

NMed

NHigh

NLow

NLow

0
2
5
8

22.8%±0.62%
26.6%±0.25%
37.0%±0.42%

19.9%±0.07%
39.6%±0.65%
52.0%±0.66%

23.6%±0.46%
31.1%±0.69%
54.6%±0.41%

16.8%±0.19%
37.8%±0.83%
57.8%±0.04%

57.7%±0.21%
63.9%±0.15%
65.1%±0.01%

5.4.2.5 Prediction of Cholesterol Removal in Plaque Based on the Current Models
Shown in Table 16 is the estimated percentage of cholesterol removed from
plaque within 8 days, assuming that the lesion is composed of 22% cholesterol (Kaiz,
1976) and that the combined degradation rate equations in Tables 11 and 12 are used in
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Table 16 for the atomized and inkjet bacteria were calculated per mL of alginate. As can
be seen, the inkjet case resulted in the highest degradation of cholesterol in plaque within
the 8-day duration.
Table 16. Estimated time to fully degrade cholesterol from intermediate-stage plaque
lesion.!
NLow
%Cholesterol
Removed

Free Bacteria
NMed
NHigh

22.19%

34.65% 31.23%

NLow
41.51%

Atomized
NMed

NHigh

Inkjet
NLow

32.70% 38.53% 61.80%

5.5 Partition Coefficient Determination
Shown in Table 17 and Fig. 37, are the partition coefficients of cholesterol
extracted from water into chloroform according to the scheme in Fig. 5 at various
sampling times. Theoretically, the partition coefficient is a constant and should not vary
unless a new component is introduced in the mixture or there is a change in pH or
temperature, thus shifting the solubilities (Harrison, 2003). A decrease in K values is
observed for the free and immobilized bacteria as a function of time. Two hypotheses
could be formulated to justify this observation: 1) The biosurfactant is amphipathic and
thus the cholesterol has adsorbed upon to the bio-surfactant itself and was not stripped off
by the chloroform during extraction, and/or, 2) The hydrophobic cholesterol adsorbed to
the alginate membrane was not stripped off during the same extraction process. Both
hypotheses lead to the presence of residual amounts of solute due non-ideal efficiency of
extraction procedures. Since the same monotonous trend is observed in all scenarios, it is
safe to attribute the root cause of the K value decrease to a systematic error. The average
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partition coefficient for the inkjet-immobilized bacteria is lower during the entire
sampling interval. This could be due to the presence of chitosan in the immobilized
matrix, absent in case of the atomized alginate. The extraction protocol needs to be
further optimized to take the presence of this additional bio-polymer coating into account.

Experimentally Determined
Partition Coefficient (K)

Table 17. Average partition coefficients of cholesterol extracted from water into
chloroform (N = 3).
Partition Coefficient (K)
NLow
NMed
NHigh
Atomized
Free
Free

Time
(days)

NLow
Free

0
2
5
8

1.64E+01
4.74E+00
4.08E+00
2.78E+00

1.64E+01
6.10E+00
2.70E+00
1.32E+00

1.64E+01
5.34E+00
2.53E+00
1.63E+00

18.00

1.64E+01
4.58E+00
3.43E+00
1.49E+00

Inkjet
5.12E+00
3.20E+00
2.25E+00
2.11E+00

Medium Free

16.00

Low Free

14.00

High Free

12.00

Atomized Low

10.00

Inkjet Low

8.00
6.00
4.00
2.00
0.00
0

2

4

6

8

10
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Figure 37. Experimentally determined partition coefficient of cholesterol extracted from
water into chloroform.
!
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6.0 DISCUSSION!
The studies from the literature that compared most closely with this study were
those of Goetschel, et al and Bianchi, et al. Goetschel, et al, reported a 33% degradation
of cholesterol in 24 h in aqueous medium by free bacteria. Bianchi, et al reported that
free and chitin-encapsulated R. erythropolis converted nearly all and 97% of total
cholesterol, respectively, within 3 days.
The percentage degradation data reported in Table 15 for the first 48 h were
slightly lower but not significantly different from the 33% reported by Goetschel, et al.
The percentage degradation reported by Bianchi, et al, however, was much greater than
that of the data reported in this study. Several factors may have contributed to these
differences. The first thing to note is that Bianchi, et al did not specify the initial amount
of cholesterol that they used. Assuming the rate of cholesterol degradation did not
change with the amount of cholesterol present within the system, if a small initial amount
of cholesterol was used, less time would be required for it to be degraded. Second,
Bianchi, et al used a BHI growth medium, whereas LB Broth, PBS, and BSA were used
in this study. Hence, growth characteristics were expected to be different. Changes in
growth characteristics would include differences in the enzyme production and cell
survivability. Perhaps, the most important thing to consider is that the optimized medium
in this study was designed to decrease the amount of biosurfactant being produced. Since
the biosurfactant is amphipathic, it is possible that it played a role in cholesterol
degradation. With regards to the case of encapsulated bacteria, Bianchi, et al worked
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with chitin polymer as opposed to Ca-alginate, which was used in this study. Hence,
there is no baseline from which a conclusion may be reached.
Prior to the bio-surfactant minimization efforts, it was initially hypothesized that
cholesterol diffusion could be described using Fick’s Second Law of Diffusion.
However, due to bio-surfactant growth the extent of diffusive and kinetic mechanisms
contributing to cholesterol degradation was considered as a lump degradation
mechanism. It is possible that the biosurfactant may have aided in some type of cotransport mechanism whereby hydrophobic cholesterol was physically transported from
the medium into the capsule where it could have been degraded by bacteria. More
studies would need to be conducted in order to understand the interaction of biosurfactant
with cholesterol degradation. Due to the enhanced metabolic capability of the
miniaturized inkjet capsules immobilizing the bacteria, the above-stated hypothesis is
partially validated. This observation is in alignment with the results of a recent study on
fluorescent MW markers demonstration a 4-fold diffusivity increase across miniaturized
alginate beads (Mobed-Miremadi, 2012).
The following hypotheses justifying the higher degradation rates for the bacteria
immobilized using the inkjet process could be formulated:
i. The S/V ratio of inkjet bacteria was 26 times higher than that of the atomized bacteria;
ii. Hydrophobic cholesterol adsorbs onto the surface of the capsules;
iii. The pore size range for both capsules has been measured to be approximately 6 nm.
The Stoke’s radius of cholesterol is a = 0.54 nm, hence the metabolite can freely diffuse.

! ""!

iv. The presence of the chitosan membrane may have also had some interaction with the
cholesterol, which would require further investigation.
Cholesterol degradation using the low bacterial cell count condition during the lag
phase may have mostly occurred by way of the intracellular enzyme from t = 0 to t = 5
days. It is likely that by the time the last measurement was taken at t = 8 days, the
bacteria were beginning to produce the extracellular enzyme. Encapsulating bacteria
harvested from the plateau phase by way of inkjet bioprinting followed by a cholesterol
degradation study would confirm this hypothesis. Furthermore, the molecular weight of
the cholesterol oxidase enzyme is below the molecular weight cut-off of alginate, which
is approximately 70 kDa, so it is possible that the extracellular enzyme had diffused out
of the capsules and degraded cholesterol in the medium. More studies would need to be
conducted in order to confirm this postulated hypothesis.
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7.0 POSSIBLE CONTRIBUTIONS TO KNOWLEDGE!
•

The composition of bacteria growth medium was optimized in order to minimize the
production of biosurfactant. Without this optimization, the cholesterol degradation
studies would have been hindered.

•

To date, the only membranes used to encapsulate R. erythropolis (ATCC 25544) were
chitin and liposomes as compared to Ca-alginate, which was used in this study.
Studies of cholesterol degradation with encapsulated bacteria have not been
characterized for the case of miniaturization, which has been proven to be the most
effective alternative for medical applications.

•

One of the major feats of this research was overcoming the hydrophobic nature of the
cholesterol powder suspended in the aqueous medium. It was the hydrophobicity of
the cholesterol that necessitated the use of destructive sampling throughout
experimentation. Custom extraction layer identification and protocols have been
developed.

!
!
!
!
!
!
!
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8.0 CONCLUSIONS AND FUTURE WORK
8.1 Conclusion
Initially, bacterial cell growth was hindered due to biosurfactant production as a
metabolic by-product. The constituents of the growth medium were optimized using an
L16 Taguchi design in order to minimize the production of biosurfactant with the
intention of characterizing growth data for free and atomized bacteria. The validity of the
biosurfactant minimization efforts was proven by the stabilization of the amount of
trehalose-glycolipid produced, measured post-optimization, in conjunction with the
growth curves.
Detailed extraction methods were developed for cholesterol and biosurfactant
from free and encapsulated bacteria systems. Simple extraction by use of (2:1, v/v)
chloroform:methanol mixture resulted in biphasic separation through which cholesterol
and biosurfactant were chemically separated and subsequently quantified using
colorimetric methods. By overcoming the challenge of the hydrophobicity of cholesterol
characterization in aqueous media, the colorimetric quantification of cholesterol was
made possible.
It was empirically shown that there was no significant difference in cholesterol
degradation rate as cell number was varied. It was also empirically shown that cell
number did not have a significant effect on cholesterol degradation rate for immobilized
bacteria. It was shown that the highest cholesterol degradation rate was obtained using
lag phase bacteria immobilized by inkjet bioprinting.
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8.2 Future Work
A recommended future step for this research study would be to increase the
sampling frequency to between 0 and 2 days in order to obtain a better understanding of
the cholesterol degradation profile. Furthermore, the study could be advanced through
the genetic engineering of the bacterium in order to accelerate the cholesterol degradation
rate by way of transfecting mammalian stem cells.
Another suggested area of study would be the examination of interaction(s)
between cholesterol and biosurfactant in order to confirm the presence of co-transport
mechanisms. Mathematical models could then be derived for co-transport mechanisms of
various substances by biosurfactants.
Also, the use of more sensitive measurement methodologies should be considered
to obtain more accurate metabolite degradation rates. One such example would be to
quantify the amount of 4-cholesten-3-one using gas chromatography and mass
spectrometry (GC-MS) techniques in order to confirm the extent of cholesterol
conversion.

!
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10.0 APPENDIX
10.1 APPENDIX A: DOE DATA

Figure 38. Main effects plot for means for bacteria growth for t = 24 h.!

Figure 39. Main effects plot for signal-to-noise ratios for t = 24 h.
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Figure 40. Main effects plot for means for bacteria growth for t = 48 h.

Figure 41. Main effects plot for signal-to-noise ratios for bacteria growth for t = 48 h.
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Figure 42. Main effects plot for means for glycolipid biosurfactant for t = 24 h.

Figure 43. Main effects plot for signal-to-noise ratios for glycolipid biosurfactant for t =
24 h!"
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Table 18. DOE raw data for biosurfactant mass and bacteria growth at t = 48h.
Experiment No.

Mass of Biosurfactant in mg
(t = 48 h)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

10.81
22.51
34.53
26.80
23.03
25.28
19.35
16.85
27.90
17.09
26.71
16.21
22.69
26.31
21.74
23.28
10.34
23.06
29.41
25.53
21.38
24.66
19.83
24.01
30.64
16.40
25.05
17.22
26.44
25.81
22.25
24.39
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Bacteria Growth
in %T
(t = 48 h)
98.25
91.78
71.73
64.07
66.47
84.11
92.63
88.17
90.61
86.89
82.49
97.07
92.82
84.74
91.26
70.94
99.77
93.87
72.75
67.73
67.94
87.71
95.05
90.94
93.34
87.08
85.24
96.45
97.11
87.18
94.51
70.88

10.2 APPENDIX B: CHOLESTEROL DEGRADATION PROFILES
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Figure 44. Cholesterol profile of free bacteria with medium cell count.
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Figure 45. Cholesterol profile of free bacteria with high cell count.
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Figure 46. Cholesterol profile of atomized bacteria with medium cell count.
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Figure 47. Cholesterol profile of atomized bacteria with high cell count.
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